Over the last six decades, tremendous strides have been made in the development of safe, efficacious and 'patient-friendly' modalities of testosterone replacement therapy in men. The most recent forms of androgen replacement that are in widespread use include testosterone patch and gel. These preparations are convenient in their use and deliver a physiological amount of testosterone. Although these transdermal preparations are gaining popularity, many hypogonadal men still receive treatment with intramuscular esters. Testosterone enanthate remains the most commonly prescribed ester. Although testosterone esters are efficacious in terms of improving bone and muscle mass, they possess unfavourable pharmacokinetics that result in fluctuations in the mood, energy and sexual function of patients. Furthermore, these esters need to be injected every 2-4 weeks. Hence, there has been a need to develop long-acting esters that can be administered infrequently and deliver a physiological amount of testosterone without major fluctuations. Recently, injectable testosterone undecanoate (Nebido) has become available in Europe and will soon be marketed in south America, Asia and Australia. In this paper, the structure, pharmacokinetics, efficacy and side-effect profile of testosterone undecanoate will be reviewed and also compared with other existing testosterone esters.
Jockenhövel F. Jockenhövel F. Aging Male. 2004 Dec;7(4):319-24. doi: 10.1080/13685530400016557. Aging Male. 2004. PMID: 15799128 Review.
Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M. Morales A, et al. Aging Male. 2006 Dec;9(4):221-7. doi: 10.1080/13685530601063689. Aging Male. 2006. PMID: 17178558
[No authors listed] [No authors listed] Drugs R D. 2003;4(1):72-4. doi: 10.2165/00126839-200304010-00015. Drugs R D. 2003. PMID: 12568644 Review. No abstract available.
Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. Zitzmann M, et al. J Sex Med. 2013 Feb;10(2):579-88. doi: 10.1111/j.1743-6109.2012.02853.x. Epub 2012 Jul 19. J Sex Med. 2013. PMID: 22812645 Clinical Trial.
Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Ernst M. Jockenhövel F, et al. Eur J Endocrinol. 2009 May;160(5):815-9. doi: 10.1530/EJE-08-0830. Epub 2009 Feb 18. Eur J Endocrinol. 2009. PMID: 19225035 Clinical Trial.
Adam JA, Pastuszak AW, Christensen MB, Spencer R, Sandberg A, Hotaling JM, Lipshultz LI. Adam JA, et al. Int J Impot Res. 2023 Aug;35(5):439-446. doi: 10.1038/s41443-022-00585-1. Epub 2022 May 24. Int J Impot Res. 2023. PMID: 35610506 Review.
Alexandraki KI, Grossman A. Alexandraki KI, et al. J Clin Med. 2019 Dec 5;8(12):2153. doi: 10.3390/jcm8122153. J Clin Med. 2019. PMID: 31817511 Free PMC article. Review.
Tatham LM, Liptrott NJ, Rannard SP, Owen A. Tatham LM, et al. Molecules. 2019 Jul 24;24(15):2685. doi: 10.3390/molecules24152685. Molecules. 2019. PMID: 31344834 Free PMC article.
Fabris B, Bernardi S, Trombetta C. Fabris B, et al. J Endocrinol Invest. 2015 Mar;38(3):269-82. doi: 10.1007/s40618-014-0186-2. Epub 2014 Nov 18. J Endocrinol Invest. 2015. PMID: 25403429 Review.
Bang JK, Lim JJ, Choi J, Won HJ, Yoon TK, Hong JY, Park DS, Song SH. Bang JK, et al. Yonsei Med J. 2013 May 1;54(3):702-6. doi: 10.3349/ymj.2013.54.3.702. Yonsei Med J. 2013. PMID: 23549818 Free PMC article.